Cargando…
The Cardioprotective Mechanism of Phenylaminoethyl Selenides (PAESe) Against Doxorubicin-Induced Cardiotoxicity Involves Frataxin
Doxorubicin (DOX) is an anthracycline cancer chemotherapeutic that exhibits cumulative dose-limiting cardiotoxicity and limits its clinical utility. DOX treatment results in the development of morbid cardiac hypertrophy that progresses to congestive heart failure and death. Recent evidence suggests...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8072348/ https://www.ncbi.nlm.nih.gov/pubmed/33912028 http://dx.doi.org/10.3389/fphar.2020.574656 |
_version_ | 1783683900264939520 |
---|---|
author | Fu, Xiaoyu Eggert, Mathew Yoo, Sieun Patel, Nikhil Zhong, Juming Steinke, Ian Govindarajulu, Manoj Turumtay, Emine Akyuz Mouli, Shravanthi Panizzi, Peter Beyers, Ronald Denney, Thomas Arnold, Robert Amin, Rajesh H. |
author_facet | Fu, Xiaoyu Eggert, Mathew Yoo, Sieun Patel, Nikhil Zhong, Juming Steinke, Ian Govindarajulu, Manoj Turumtay, Emine Akyuz Mouli, Shravanthi Panizzi, Peter Beyers, Ronald Denney, Thomas Arnold, Robert Amin, Rajesh H. |
author_sort | Fu, Xiaoyu |
collection | PubMed |
description | Doxorubicin (DOX) is an anthracycline cancer chemotherapeutic that exhibits cumulative dose-limiting cardiotoxicity and limits its clinical utility. DOX treatment results in the development of morbid cardiac hypertrophy that progresses to congestive heart failure and death. Recent evidence suggests that during the development of DOX mediated cardiac hypertrophy, mitochondrial energetics are severely compromised, thus priming the cardiomyocyte for failure. To mitigate cumulative dose (5 mg/kg, QIW x 4 weeks with 2 weeks recovery) dependent DOX, mediated cardiac hypertrophy, we applied an orally active selenium based compound termed phenylaminoethyl selenides (PAESe) (QIW 10 mg/kg x 5) to our animal model and observed that PAESe attenuates DOX-mediated cardiac hypertrophy in athymic mice, as observed by MRI analysis. Mechanistically, we demonstrated that DOX impedes the stability of the iron-sulfur cluster biogenesis protein Frataxin (FXN) (0.5 fold), resulting in enhanced mitochondrial free iron accumulation (2.5 fold) and reduced aconitase activity (0.4 fold). Our findings further indicate that PAESe prevented the reduction of FXN levels and the ensuing elevation of mitochondrial free iron levels. PAESe has been shown to have anti-oxidative properties in part, by regeneration of glutathione levels. Therefore, we observed that PAESe can mitigate DOX mediated cardiac hypertrophy by enhancing glutathione activity (0.4 fold) and inhibiting ROS formation (1.8 fold). Lastly, we observed that DOX significantly reduced cellular respiration (basal (5%) and uncoupled (10%)) in H9C2 cardiomyoblasts and that PAESe protects against the DOX-mediated attenuation of cellular respiration. In conclusion, the current study determined the protective mechanism of PAESe against DOX mediated myocardial damage and that FXN is implicitly involved in DOX-mediated cardiotoxicity. |
format | Online Article Text |
id | pubmed-8072348 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80723482021-04-27 The Cardioprotective Mechanism of Phenylaminoethyl Selenides (PAESe) Against Doxorubicin-Induced Cardiotoxicity Involves Frataxin Fu, Xiaoyu Eggert, Mathew Yoo, Sieun Patel, Nikhil Zhong, Juming Steinke, Ian Govindarajulu, Manoj Turumtay, Emine Akyuz Mouli, Shravanthi Panizzi, Peter Beyers, Ronald Denney, Thomas Arnold, Robert Amin, Rajesh H. Front Pharmacol Pharmacology Doxorubicin (DOX) is an anthracycline cancer chemotherapeutic that exhibits cumulative dose-limiting cardiotoxicity and limits its clinical utility. DOX treatment results in the development of morbid cardiac hypertrophy that progresses to congestive heart failure and death. Recent evidence suggests that during the development of DOX mediated cardiac hypertrophy, mitochondrial energetics are severely compromised, thus priming the cardiomyocyte for failure. To mitigate cumulative dose (5 mg/kg, QIW x 4 weeks with 2 weeks recovery) dependent DOX, mediated cardiac hypertrophy, we applied an orally active selenium based compound termed phenylaminoethyl selenides (PAESe) (QIW 10 mg/kg x 5) to our animal model and observed that PAESe attenuates DOX-mediated cardiac hypertrophy in athymic mice, as observed by MRI analysis. Mechanistically, we demonstrated that DOX impedes the stability of the iron-sulfur cluster biogenesis protein Frataxin (FXN) (0.5 fold), resulting in enhanced mitochondrial free iron accumulation (2.5 fold) and reduced aconitase activity (0.4 fold). Our findings further indicate that PAESe prevented the reduction of FXN levels and the ensuing elevation of mitochondrial free iron levels. PAESe has been shown to have anti-oxidative properties in part, by regeneration of glutathione levels. Therefore, we observed that PAESe can mitigate DOX mediated cardiac hypertrophy by enhancing glutathione activity (0.4 fold) and inhibiting ROS formation (1.8 fold). Lastly, we observed that DOX significantly reduced cellular respiration (basal (5%) and uncoupled (10%)) in H9C2 cardiomyoblasts and that PAESe protects against the DOX-mediated attenuation of cellular respiration. In conclusion, the current study determined the protective mechanism of PAESe against DOX mediated myocardial damage and that FXN is implicitly involved in DOX-mediated cardiotoxicity. Frontiers Media S.A. 2021-04-12 /pmc/articles/PMC8072348/ /pubmed/33912028 http://dx.doi.org/10.3389/fphar.2020.574656 Text en Copyright © 2021 Fu, Eggert, Yoo, Patel, Zhong, Steinke, Govindarajulu, Turumtay, Mouli, Panizzi, Beyers, Denney, Arnold and Amin. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Fu, Xiaoyu Eggert, Mathew Yoo, Sieun Patel, Nikhil Zhong, Juming Steinke, Ian Govindarajulu, Manoj Turumtay, Emine Akyuz Mouli, Shravanthi Panizzi, Peter Beyers, Ronald Denney, Thomas Arnold, Robert Amin, Rajesh H. The Cardioprotective Mechanism of Phenylaminoethyl Selenides (PAESe) Against Doxorubicin-Induced Cardiotoxicity Involves Frataxin |
title | The Cardioprotective Mechanism of Phenylaminoethyl Selenides (PAESe) Against Doxorubicin-Induced Cardiotoxicity Involves Frataxin |
title_full | The Cardioprotective Mechanism of Phenylaminoethyl Selenides (PAESe) Against Doxorubicin-Induced Cardiotoxicity Involves Frataxin |
title_fullStr | The Cardioprotective Mechanism of Phenylaminoethyl Selenides (PAESe) Against Doxorubicin-Induced Cardiotoxicity Involves Frataxin |
title_full_unstemmed | The Cardioprotective Mechanism of Phenylaminoethyl Selenides (PAESe) Against Doxorubicin-Induced Cardiotoxicity Involves Frataxin |
title_short | The Cardioprotective Mechanism of Phenylaminoethyl Selenides (PAESe) Against Doxorubicin-Induced Cardiotoxicity Involves Frataxin |
title_sort | cardioprotective mechanism of phenylaminoethyl selenides (paese) against doxorubicin-induced cardiotoxicity involves frataxin |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8072348/ https://www.ncbi.nlm.nih.gov/pubmed/33912028 http://dx.doi.org/10.3389/fphar.2020.574656 |
work_keys_str_mv | AT fuxiaoyu thecardioprotectivemechanismofphenylaminoethylselenidespaeseagainstdoxorubicininducedcardiotoxicityinvolvesfrataxin AT eggertmathew thecardioprotectivemechanismofphenylaminoethylselenidespaeseagainstdoxorubicininducedcardiotoxicityinvolvesfrataxin AT yoosieun thecardioprotectivemechanismofphenylaminoethylselenidespaeseagainstdoxorubicininducedcardiotoxicityinvolvesfrataxin AT patelnikhil thecardioprotectivemechanismofphenylaminoethylselenidespaeseagainstdoxorubicininducedcardiotoxicityinvolvesfrataxin AT zhongjuming thecardioprotectivemechanismofphenylaminoethylselenidespaeseagainstdoxorubicininducedcardiotoxicityinvolvesfrataxin AT steinkeian thecardioprotectivemechanismofphenylaminoethylselenidespaeseagainstdoxorubicininducedcardiotoxicityinvolvesfrataxin AT govindarajulumanoj thecardioprotectivemechanismofphenylaminoethylselenidespaeseagainstdoxorubicininducedcardiotoxicityinvolvesfrataxin AT turumtayemineakyuz thecardioprotectivemechanismofphenylaminoethylselenidespaeseagainstdoxorubicininducedcardiotoxicityinvolvesfrataxin AT moulishravanthi thecardioprotectivemechanismofphenylaminoethylselenidespaeseagainstdoxorubicininducedcardiotoxicityinvolvesfrataxin AT panizzipeter thecardioprotectivemechanismofphenylaminoethylselenidespaeseagainstdoxorubicininducedcardiotoxicityinvolvesfrataxin AT beyersronald thecardioprotectivemechanismofphenylaminoethylselenidespaeseagainstdoxorubicininducedcardiotoxicityinvolvesfrataxin AT denneythomas thecardioprotectivemechanismofphenylaminoethylselenidespaeseagainstdoxorubicininducedcardiotoxicityinvolvesfrataxin AT arnoldrobert thecardioprotectivemechanismofphenylaminoethylselenidespaeseagainstdoxorubicininducedcardiotoxicityinvolvesfrataxin AT aminrajeshh thecardioprotectivemechanismofphenylaminoethylselenidespaeseagainstdoxorubicininducedcardiotoxicityinvolvesfrataxin AT fuxiaoyu cardioprotectivemechanismofphenylaminoethylselenidespaeseagainstdoxorubicininducedcardiotoxicityinvolvesfrataxin AT eggertmathew cardioprotectivemechanismofphenylaminoethylselenidespaeseagainstdoxorubicininducedcardiotoxicityinvolvesfrataxin AT yoosieun cardioprotectivemechanismofphenylaminoethylselenidespaeseagainstdoxorubicininducedcardiotoxicityinvolvesfrataxin AT patelnikhil cardioprotectivemechanismofphenylaminoethylselenidespaeseagainstdoxorubicininducedcardiotoxicityinvolvesfrataxin AT zhongjuming cardioprotectivemechanismofphenylaminoethylselenidespaeseagainstdoxorubicininducedcardiotoxicityinvolvesfrataxin AT steinkeian cardioprotectivemechanismofphenylaminoethylselenidespaeseagainstdoxorubicininducedcardiotoxicityinvolvesfrataxin AT govindarajulumanoj cardioprotectivemechanismofphenylaminoethylselenidespaeseagainstdoxorubicininducedcardiotoxicityinvolvesfrataxin AT turumtayemineakyuz cardioprotectivemechanismofphenylaminoethylselenidespaeseagainstdoxorubicininducedcardiotoxicityinvolvesfrataxin AT moulishravanthi cardioprotectivemechanismofphenylaminoethylselenidespaeseagainstdoxorubicininducedcardiotoxicityinvolvesfrataxin AT panizzipeter cardioprotectivemechanismofphenylaminoethylselenidespaeseagainstdoxorubicininducedcardiotoxicityinvolvesfrataxin AT beyersronald cardioprotectivemechanismofphenylaminoethylselenidespaeseagainstdoxorubicininducedcardiotoxicityinvolvesfrataxin AT denneythomas cardioprotectivemechanismofphenylaminoethylselenidespaeseagainstdoxorubicininducedcardiotoxicityinvolvesfrataxin AT arnoldrobert cardioprotectivemechanismofphenylaminoethylselenidespaeseagainstdoxorubicininducedcardiotoxicityinvolvesfrataxin AT aminrajeshh cardioprotectivemechanismofphenylaminoethylselenidespaeseagainstdoxorubicininducedcardiotoxicityinvolvesfrataxin |